Stock Financial Ratios and Split History
ICAD / icad, inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||72.09|
|Enterprise Value ($M)||62.74|
|Book Value ($M)||25.04|
|Book Value / Share||1.55|
|Price / Book||3.17|
|NCAV / Share||1.62|
|Price / NCAV||12.20|
|Income Statement (mra) ($M)|
|Balance Sheet (mrq) ($M)|
|Cash & Equivalents||11.26|
|Cash / Share||0.70|
|Common Stock Shares Outstanding||16,074,832|
|Common Shares Outstanding||16,157,466|
|Weighted Average Number Of Diluted Shares Outstanding||15,932,000|
|Weighted Average Number Of Shares Outstanding Basic||15,932,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Cash Conversion Cycle||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-0.40|
|Return on Assets (ROA)||-0.26|
|Return on Equity (ROE)||-0.40|
|Identifiers and Descriptors|
|Central Index Key (CIK)||749660|
|SIC 3841 - Surgical and Medical Instruments and Apparatus|
Stock splits are used by icad, inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
Peers - Surgical and Medical Instruments and Apparatus (3841)
PAVM / PAVmed Inc.
PAVMW / PAVmed Inc.
PAVMU / PAVmed Inc.
BTCY / Biotricity Inc.
Related News Stories
Good day, and welcome to the iCAD Medical Third Quarter 2017 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the conference over to Bob Yedid, with LifeSci Advisors. Please go ahead. (20-0)